The use of recombinant gamma interferon associated with pentavalent antimony in therapy for visceral leishmaniasis

Badaró, Roberto

doi:10.1590/s0074-02761988000500028

Cited by 4 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is clinically well-tolerated (111), and repeat treatment with IFN-γ plus Sb V has been shown to be effective in patients with Sb V -refractive disease, yielding a >80% cure rate in VL (112, 113, 121). Studies in untreated patients with VL demonstrated that the addition of IFN-γ as immunotherapy accelerated parasitological control (122, 123) and enhanced the clinical efficacy of conventional Sb V therapy (123).…”

Section: Approaches Used In Humansmentioning

confidence: 99%

Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease

et al. 2014

View full text Add to dashboard Cite

Leishmaniasis has several clinical forms: self-healing or chronic cutaneous leishmaniasis or post-kala-azar dermal leishmaniasis; mucosal leishmaniasis; visceral leishmaniasis (VL), which is fatal if left untreated. The epidemiology and clinical features of VL vary greatly due to the interaction of multiple factors including parasite strains, vectors, host genetics, and the environment. Human immunodeficiency virus infection augments the severity of VL increasing the risk of developing active disease by 100–2320 times. An effective vaccine for humans is not yet available. Resistance to chemotherapy is a growing problem in many regions, and the costs associated with drug identification and development, make commercial production for leishmaniasis, unattractive. The toxicity of currently drugs, their long treatment course, and limited efficacy are significant concerns. For cutaneous disease, many studies have shown promising results with immunotherapy/immunochemotherapy, aimed to modulate and activate the immune response to obtain a therapeutic cure. Nowadays, the focus of many groups centers on treating canine VL by using vaccines and immunomodulators with or without chemotherapy. In human disease, the use of cytokines like interferon-γ associated with pentavalent antimonials demonstrated promising results in patients that did not respond to conventional treatment. In mice, immunomodulation based on monoclonal antibodies to remove endogenous immunosuppressive cytokines (interleukin-10) or block their receptors, antigen-pulsed syngeneic dendritic cells, or biological products like Pam3Cys (TLR ligand) has already been shown as a prospective treatment of the disease. This review addresses VL treatment, particularly immunotherapy and/or immunochemotherapy as an alternative to conventional drug treatment in experimental models, canine VL, and human disease.

show abstract

Section: Approaches Used In Humansmentioning

confidence: 99%

Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Accelerated clearance of parasite is seen on addition of IFN-γ. Treatment of VL with IFN-γ plus Sb V showed a cure rate of >80% cure rate (Badaro, 1988; Badaro et al , 1990; Sundar et al , 1994). and enhanced the clinical efficacy of conventional Sb V therapy (Sundar & Murray, 1995).…”

Section: Introductionmentioning

confidence: 99%

“…Accelerated clearance of parasite is seen on addition of IFN- γ . Treatment of VL with IFN- γ plus Sb V showed a cure rate of >80% cure rate (Badaro, 1988; Badaro et al 1990; Sundar et al 1994) and enhanced the clinical efficacy of conventional Sb V therapy (Sundar and Murray, 1995). Similarly, results were seen in a study in Kenya where Sb V or Sb V plus IFN- γ for 30 days was given in two groups for VL treatment with combination therapy showing quick parasite clearance (Squires et al 1993).…”

Section: Introductionmentioning

confidence: 99%

Chemotherapeutics of visceral leishmaniasis: present and future developments

2017

View full text Add to dashboard Cite

Treatment of Visceral Leishmaniasis (VL), a neglected tropical disease, is very challenging with few treatment options. Long duration of treatment and drug toxicity further limit the target of achieving VL elimination. Chemotherapy remains the treatment of choice. Single dose of liposomal amphotericin B (LAmB) and multidrug therapy (LAmB + miltefosine, LAmB + paromomycin (PM), or miltefosine + PM) are recommended treatment regimen for treatment of VL in Indian sub-continent. Combination therapy of pentavalent antimonials (Sbv) and PM in East Africa and LAmB in the Mediterranean region/South America remains the treatment of choice. Various drugs having anti-leishmania properties are in preclinical phase and need further development. An effective treatment and secondary prophylaxis of HIV-VL co-infection should be developed to decrease treatment failure and drug resistance.

show abstract

“…IFN‐γ‐1b protein is administered with sodium antimony gluconate. It was found to be well tolerated and effective in patients with VLs refractory to monotherapy with pentavalent antimonial therapy 24,25 . Use of IFN‐γ in untreated cases of VL led to accelerated parasitological control 26,27 along with increased clinical efficacy of pentavalent antimonial therapy 27 .…”

Section: Newer Options: Immunotherapymentioning

confidence: 99%

“…It was found to be well tolerated and effective in patients with VLs refractory to monotherapy with pentavalent antimonial therapy. 24,25 Use of IFN-c in untreated cases of VL led to accelerated parasitological control 26,27 along with increased clinical efficacy of pentavalent antimonial therapy. 27 In the study of Squires et al, combination of IFN-c and pentavalent antimonial therapy for 1 month produced a negative spleen culture more quickly among patients with VL.…”

Section: Interferonsmentioning

confidence: 99%

Treatment options for leishmaniasis

Pradhan

Schwartz

Patil

et al. 2021

Clin Experimental Derm

View full text Add to dashboard Cite

Summary Leishmaniasis is broadly classified into three types: cutaneous, mucocutaneous and visceral. The visceral form is most dangerous and can result in death. Although leishmaniasis is an ancient disease, its treatment is still challenging. Several drugs, differing in their cost, toxicity, treatment duration and emergence of drug resistance, are used for different types of leishmaniasis. To overcome these limitations, the search for newer drugs and other treatments continues. In this article, we discuss conventional drugs, other treatments, including newer options such as immunotherapy and immunochemotherapy, and future prospects for leishmaniasis treatment.

show abstract

The use of recombinant gamma interferon associated with pentavalent antimony in therapy for visceral leishmaniasis

Cited by 4 publications

References 0 publications

Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease

Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease

Chemotherapeutics of visceral leishmaniasis: present and future developments

Treatment options for leishmaniasis

Contact Info

Product

Resources

About